Archives: Press Releases
Modulus Discovery Announces the Appointment of Hiroko Nishimoto As Advisor
News -
01 June, 2018 -
Modulus Discovery, Inc., an early stage global biopharmaceutical company, announced today the appointment of Hiroko Nishimoto as Advisor to the Company. Ms. Nishimoto has more than 14 years of pharmaceutical business experience including corporate strategy, business development, external affairs, and CSR at Astellas Pharma Inc.. As a liaison of the Japan Pharmaceutical Manufacturers Association, she ...continuedModulus Discovery Announces the Appointment of Taisuke Takahashi, Ph.D. as Vice President and Head Of Chemistry
News -
01 April, 2018 -
Modulus Discovery, Inc., an early stage global biopharmaceutical company with offices in Tokyo, Japan and Cambridge, MA, announced today the appointment of Taisuke Takahashi, Ph.D., as Vice President and Head of Chemistry. Dr. Takahashi joins us from Astellas Pharma where he worked for 13 years in R&D as a medicinal chemist. During his tenure, he ...continuedModulus Discovery Announces the Appointment of Yoh Terada, Ph.D. as Chief Scientific Officer
News -
02 January, 2018 -
Modulus Discovery, Inc., an early stage global biopharmaceutical company with offices in Tokyo, Japan and Cambridge, MA, announced today the appointment of Yoh Terada, Ph.D., as Chief Scientific Officer of Modulus Discovery. Dr. Terada joins Modulus from Astellas Pharma, where he worked for nearly twenty years in various senior disease biology R&D and management capacities. ...continuedModulus Discovery Establishes Wholly Owned U.S. Subsidiary and R&D Office in Cambridge, MA
News -
15 December, 2017 -
Modulus Discovery, Inc., an early stage drug discovery company announced today the establishment of a wholly owned U.S. subsidiary, and the opening of a new R&D office in Cambridge, Massachusetts. This development is part of the company’s larger vision to build an innovative and globally integrated technology-driven virtual pharma company. Cambridge, MA, has long been ...continuedModulus Discovery Announces the Appointment of Koji Tsuda As Scientific Advisor
News -
11 October, 2017 -
Modulus Discovery, Inc., an early stage global biopharmaceutical company, announced today the appointment of Professor Koji Tsuda, Ph.D. as Scientific Advisor to the Company. Dr. Tsuda is Professor of Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, at The University of Tokyo. He is well recognized for his work in machine ...continuedModulus Discovery Announces the Appointment of Yutaka Akiyama as Scientific Advisor
News -
01 October, 2017 -
Modulus Discovery, Inc., an early stage global biopharmaceutical company, announced today the appointment of Professor Yutaka Akiyama, Ph.D , as Scientific Advisor to the Company. Dr. Akiyama is a professor at Department of Computer Science, School of Computing, Tokyo Institute of Technology. He is well recognized for his work in big data analysis in the ...continuedModulus Discovery Receives Amazon Web Services AWS Activate Program and Google Cloud Startup Awards
News -
09 September, 2017 -
Modulus Discovery, Inc., an early stage global biopharmaceutical company with offices in Tokyo, Japan and Cambridge, MA, is pleased to announce that it has received awards from the Google Startup and Amazon Web Services (AWS) Activate Programs. The Google Startup and AWS Activate Programs award eligible and qualified startup ventures with significant computational services and ...continuedModulus Discovery Announces Appointment of Osamu Nureki As Scientific Advisor
News -
01 August, 2017 -
Modulus Discovery, Inc., an early stage global biopharmaceutical company, announced today the appointment of Professor Osamu Nureki, Ph.D. as Scientific Advisor to the Company. Dr. Nureki is Professor of Department of Biological Sciences, Graduate School of Science, University of Tokyo. A globally recognized figure in the field of protein crystallography, he is most known for ...continuedPeptiDream Signs Strategic Discovery Collaboration Agreement with Modulus Discovery, Inc.,
News -
20 June, 2017 -
PeptiDream Inc., a Tokyo-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) and Modulus Discovery Inc., a Tokyo-based drug discovery company (“Modulus”), jointly announced today that they have entered into a strategic drug discovery collaboration covering multiple discovery programs. This strategic collaboration aims to leverage the expertise of both companies to jointly discover and develop small molecule clinical candidates. PeptiDream ...continuedModulus Discovery Announces the Appointment of Taka Koda, as Vice President, Corporate Planning
News -
01 May, 2017 -
Modulus Discovery, Inc., an early stage global biopharmaceutical company in Tokyo, Japan, announced today the appointment of Taka Koda, as Vice President, Corporate Planning. Mr. Koda joins us as a consultant from TK Venture Partners, Inc. and will be in charge of finance and corporate matters at Modulus. Mr. Koda has over 12 years experiences ...continued